Novel immunotherapy combinations for genitourinary cancers
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2020.1713086
Abstract: ABSTRACT Introduction: Several immune checkpoint inhibitors are FDA-approved for metastatic/advanced RCC and urothelial carcinoma (UC) based on improvements in survival. The dendritic cell vaccine, sipuleucel-T, is also approved for patients with mCRPC, based on a… read more here.
Keywords: immunotherapy combinations; genitourinary cancers; novel immunotherapy; combinations genitourinary ... See more keywords